BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk...

DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

Syphilis and gonorrhoea diagnoses see significant increase

Syphilis and gonorrhoea diagnoses see significant increase

June 11 2018 Annual reporting of sexually transmitted infection diagnoses has increased 0.3% in...

Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

  • BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    Wednesday, 25 July 2018 13:55
  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:11
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:42
  • Syphilis and gonorrhoea diagnoses see significant increase

    Syphilis and gonorrhoea diagnoses see significant increase

    Monday, 11 June 2018 14:16
  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:08

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a pregnant woman pharmacyFebruary 12 2018

The European Medicines Agency has updated advice regarding the use of retinoids and pregnancy, and on oral retinoids’ potential impact on mental health.

Following EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) concluding its review of retinoid medicines it is recommending more stringent action around pregnancy prevention when retinoids are being used. It also wants retinoids to including a warning on the possible risk of neuropsychiatric disorders, such as depression, anxiety and mood changes.

“PRAC confirmed that all oral (taken by mouth) retinoids can have harmful effects on the unborn child and therefore must not be used during pregnancy,” says the advisory. In addition: “The oral retinoids acitretin, alitretinoin and isotretinoin must not be taken by women able to have children unless the conditions of a pregnancy prevention programme (PPP) are met.”

EMA recognises that PPPs for these retinoids were already in place in some EU Member States, but “the PRAC has now updated and harmonised the PPP to ensure it is optimal to support the discussion between the doctor and the patient on the risks of these medicines, and that it is followed in practice.

“In particular, the new PPP includes assessing patients for the likelihood of becoming pregnant, requirements around pregnancy testing and the need for effective contraception before, during and after treatment, and ensuring that patients and prescribers go through an ‘acknowledgement form’ to confirm that appropriate advice has been given. Educational materials for doctors and a reminder card for patients will also be provided.”

With regards the possible risk of neuropsychiatric disorders and oral retinoids, PRAC found there were limitations on available data, but that patients with severe skin conditions may be more vulnerable to neuropsychiatric disorders due to the nature of the disease.

“The PRAC therefore recommended that the prescribing information for all oral retinoids should include a warning about this risk, including signs and symptoms patients and their families should be aware of (such as changes in mood or behaviour).” At present, no additional warnings are anticipated for inclusion in the prescribing information for topical retinoids.

The PRAC’s final recommendations will be forwarded to the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which will adopt an opinion.

Link:
EMA statement

Clinical News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...